Table 1 Characteristics of included patients in Chinese and SEER dataset
|  | Chinese dataset (n = 2846) | SEER dataset (n = 11,414) | p-value |
|---|---|---|---|
Years of diagnosis | 2016–2020 | 2010–2015 |  |
Last follow up date | 2023 | 2020 | Â |
Age | 60.75 ± 10.07 | 65.32 ± 13.58 | P < 0.01 |
Sex |  |  | P < 0.01 |
Male | 2150(75.54) | 7097(62.18) | Â |
Female | 696(24.46) | 4317(37.82) | Â |
Tumor locationa) |  |  | P < 0.01 |
Cardia | 849(29.83) | 3493(30.6) | Â |
Fundus | 17(0.60) | 492(4.31) | Â |
Body | 536(18.83) | 1206(10.57) | Â |
Gastric antrum | 438(15.39) | 2436(21.34) | Â |
Pylorus | 29(1.02) | 337(2.95) | Â |
Lesser curvature | 101(3.55) | 1158(10.15) | Â |
Greater curvature | 14(0.49) | 580(5.08) | Â |
Overlapping | 697(24.49) | 825(7.23) | Â |
Stomach | 165(5.80) | 887(7.77) | Â |
Histologyb) |  |  | P < 0.01 |
Adenocarcinoma | 2593(91.11) | 7334(64.25) | Â |
Signet ring cell | 244(8.57) | 1766(15.47) | Â |
Other | 9(0.32) | 2314(20.27) | Â |
Gradec) |  |  | P < 0.01 |
Grade I | 44(1.55) | 1340(11.74) | Â |
Grade II | 1579(55.48) | 3163(27.71) | Â |
Grade III and IV | 1223(42.97) | 6911(60.55) | Â |
T term |  |  | P < 0.01 |
T1 | 278(9.77) | 2987(26.17) | Â |
T2 | 351(12.33) | 1675(14.67) | Â |
T3 | 747(26.25) | 4109(36.00) | Â |
T4 | 1470(51.65) | 2643(23.16) | Â |
N term |  |  | P < 0.01 |
N0 | 903(31.73) | 5295(46.39) | Â |
N1 | 545(19.15) | 2900(25.41) | Â |
N2 | 567(19.92) | 1509(13.22) | Â |
N3 | 831(29.20) | 1710(14.98) | Â |
M term |  |  | P < 0.01 |
M1 | 358(12.58) | 2012(17.63) | Â |
M0 | 2488(87.42) | 9402(82.37) | Â |
Race | Â | Â | Â |
White |  | 1538(13.47) | P < 0.01 |
Black | Â | 7729(67.72) | Â |
Other | 2846(100) | 2147(18.81) | Â |
Chemotherapy |  |  | P < 0.01 |
Yes | 2146(75.4) | 6355(55.68) | Â |
No | 700(24.6) | 5059(44.32) | Â |
Radiation |  |  | P < 0.01 |
Yes | 103(3.62) | 3918(34.33) | Â |
No | 2743(96.38) | 7496(65.67) | Â |